The pharmaceutical company AstraZeneca is expected to supply the European Union with less than half of the agreed coronavirus vaccines in the spring, during the second quarter, an EU official tells Reuters.

The official is directly involved in negotiations with the pharmaceutical company.

According to him, the company has told the union “it will deliver less than 90 million servings in the second quarter”.

The European Union released a partially encrypted contract with the permission of the pharmaceutical company in January, when the company reported delays in deliveries.

However, the agreement had concealed, among other things, how much the company had said it would deliver on a quarterly basis.

In addition, the price of the vaccine and details relating to, for example, AstraZeneca's liability in the event of late vaccination were concealed from the agreement.

  • Read more: EU publishes parts of controversial vaccine deal with AstraZeneca

However, the deal a year went public when Italian Rai released it online on Thursday.

According to the agreement, 300 million servings would eventually cost 870 million euros.

“AstraZeneca is committed to best efforts (defined below) to build capacity to produce 300 million doses at no profit or loss for AstraZeneca at a total cost of € 870 million for distribution in the EU during the first half of 2021,” the agreement states.

Under the agreement, the company pledged “best efforts” to manufacture and deliver 30 to 40 million vaccines as early as the end of 2020, 80 to 100 million doses during the first quarter of this year, and the remainder of the doses during the second quarter.

It was later estimated that the company would deliver 90 million doses in the first quarter and 180 million doses in the second quarter, Reuters reports.

However, if Reuters' data proves to be correct, the EU would only receive about 130 million doses in the first half of this year.

The agreement also shows that the company has committed not to make a profit until July this year.

It can then change the pricing of the vaccine.

According to Politico, who is familiar with the agreement, the EU can do little to delay vaccine deliveries.

According to Politico, in the agreement, the EU has waived the right to sue the pharmaceutical company if the delivery of vaccines is delayed.